Satellos Bioscience Inc. Common Stock (MSLE) - Total Assets
Based on the latest financial reports, Satellos Bioscience Inc. Common Stock (MSLE) holds total assets worth $31.89 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore MSLE operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Satellos Bioscience Inc. Common Stock - Total Assets Trend (2021–2025)
This chart illustrates how Satellos Bioscience Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See Satellos Bioscience Inc. Common Stock shareholders equity for net asset value and shareholders' equity analysis.
Satellos Bioscience Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Satellos Bioscience Inc. Common Stock's total assets of $31.89 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 30.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Satellos Bioscience Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Satellos Bioscience Inc. Common Stock (MSLE) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Satellos Bioscience Inc. Common Stock's current assets represent 100.0% of total assets in 2025, an increase from 43.3% in 2021.
- Cash Position: Cash and equivalents constituted 30.7% of total assets in 2025, down from 38.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 56.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Satellos Bioscience Inc. Common Stock Competitors by Total Assets
Key competitors of Satellos Bioscience Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
SL Science Holding Limited Ordinary Shares
NASDAQ:SLBT
|
USA | $2.82 Million |
|
REMEGEN CO. LTD YC 1
F:REG
|
Germany | €7.25 Billion |
Satellos Bioscience Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.77 | 14.16 | 6.68 |
| Quick Ratio | 7.77 | 14.16 | 6.68 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $27.78 Million | $47.28 Million | $15.22 Million |
Satellos Bioscience Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Satellos Bioscience Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.83 |
| Latest Market Cap to Assets Ratio | 5.02 |
| Asset Growth Rate (YoY) | -37.3% |
| Total Assets | $31.89 Million |
| Market Capitalization | $160.19 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Satellos Bioscience Inc. Common Stock's assets at a significant premium (5.02x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Satellos Bioscience Inc. Common Stock's assets decreased by 37.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Satellos Bioscience Inc. Common Stock (2021–2025)
The table below shows the annual total assets of Satellos Bioscience Inc. Common Stock from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $31.89 Million | -37.32% |
| 2024-12-31 | $50.88 Million | +52.36% |
| 2023-12-31 | $33.39 Million | +631.08% |
| 2022-12-31 | $4.57 Million | -53.73% |
| 2021-12-31 | $9.87 Million | -- |
About Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small m… Read more